AtaiBeckley (ATAI) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
8 Sep, 2026Opening remarks and agenda
CEO welcomed shareholders and introduced board, executive team, and advisors.
Meeting chaired in accordance with Delaware law; secretary and Inspector of Elections introduced.
Agenda, meeting rules, and notice of meeting made available via virtual portal.
Specific resolutions to be voted on
Proposal 1: Approve merger agreement with Eli Lilly and Company and Albali Acquisition Corporation.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit proxies.
Corporate governance
Quorum confirmed; meeting properly convened.
Inspector of Elections appointed and sworn in to certify voting results.
Voting conducted by proxy and online, with clear instructions for changing or submitting votes.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AtaiBeckley
- Definitive merger with Eli Lilly announced; Q2 net loss $32.5M, cash $168.8M, key trials advancing.ATAI
Q2 2026 - Shareholders to vote on a merger with Eli Lilly for $6.75 per share plus up to $2.50 in CVRs.ATAIProxy filing
- Shareholders to vote on a $6.75 per share cash merger with Eli Lilly plus CVR up to $2.50.ATAIProxy filing
- Shareholders to vote on a merger offering up to $9.25 per share, closing expected Q3 2026.ATAIProxy filing
- Shareholders to vote on acquisition by Eli Lilly, advancing novel mental health therapies.ATAIProxy filing
- Shareholders will vote on a proposed acquisition by Eli Lilly, expected to close in Q3 2026.ATAIProxy filing
- Shareholders will vote on AtaiBeckley's acquisition by Eli Lilly, with clinical programs unaffected.ATAIProxy filing
- Shareholders will vote on a proposed acquisition by Eli Lilly, with closing expected in Q3 2026.ATAIProxy filing
- Definitive acquisition agreement with Eli Lilly targets Q3 2026 closing, pending approvals.ATAIProxy filing